Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Gemini who wrote (1087)	1/19/2001 9:06:17 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1298

Cell Genesys executed a license agreement with Hoechst Marion Roussel, now Aventis Pharmaceuticals, in February 1997 for gene-activated EPO and a second undisclosed protein. The agreement provides for up to $26 million in milestone payments and fees, in addition to any royalties on future sales of these two potential gene-activated protein products. As of February 2000, Cell Genesys had received over $15 million under this license agreement, including a milestone payment for the 1998 initiation of a Phase III clinical trial for gene- activated EPO, which Hoechst Marion Roussel is developing in collaboration with Transkaryotic Therapies, Inc.

To: Gemini who wrote (1087)	1/19/2001 9:14:53 PM
From: Bosco	Respond to of 1298

Hi Allan - I believe the idea is that TKTX will need to employ a key process patented by CEGE to produce the equivalence of Epogen, if the former wins the case. Therefore, the latter will garner royalty payment. However, I do not think CEGE business model is built on this case. That is to say, if TKTX wins, CEGE will have extra gravy, but none of the previous ERs I ve read brought up this point. Instead, CEGE core is GVAX, with a huge AAV patent portfolio, plus its strong cash position and ABGX holding, and milestone payment from JTC. It is possible some people may build this potential deal with TKTX in their expectation, I don't know. If they did though, it didn't reflect in the stk price. So, my guess is that it is only tangentially affecting CEGE, the real players are the two opponents best, Bosco